Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1979 1
1981 3
1982 1
1983 3
1984 1
1985 2
1986 1
1987 6
1988 1
1989 8
1990 5
1991 5
1992 9
1993 9
1994 3
1995 2
1996 5
1997 5
1998 1
1999 1
2000 3
2001 5
2002 2
2003 2
2004 3
2005 5
2006 4
2007 1
2008 4
2009 7
2010 8
2011 5
2012 3
2013 6
2014 6
2015 2
2016 7
2017 8
2018 9
2019 14
2020 11
2021 18
2022 12
2023 12
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

206 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Infiltrating bladder urothelial carcinoma"
Page 1
Single-cell atlases link macrophages and CD8(+) T-cell subpopulations to disease progression and immunotherapy response in urothelial carcinoma.
Liang Y, Tan Y, Guan B, Guo B, Xia M, Li J, Shi Y, Yu Z, Zhang Q, Liu D, Yang X, Hao J, Gong Y, Shakeel M, Zhou L, Ci W, Li X. Liang Y, et al. Theranostics. 2022 Nov 14;12(18):7745-7759. doi: 10.7150/thno.77281. eCollection 2022. Theranostics. 2022. PMID: 36451860 Free PMC article.
Rationale: Immune checkpoint inhibitors (ICIs) have revolutionized the management of locally advanced or metastatic urothelial carcinoma. Strikingly, compared to urothelial carcinoma of the bladder (UCB), upper tract urothelial carcino …
Rationale: Immune checkpoint inhibitors (ICIs) have revolutionized the management of locally advanced or metastatic urothelial car …
An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer.
Lindskrog SV, Prip F, Lamy P, Taber A, Groeneveld CS, Birkenkamp-Demtröder K, Jensen JB, Strandgaard T, Nordentoft I, Christensen E, Sokac M, Birkbak NJ, Maretty L, Hermann GG, Petersen AC, Weyerer V, Grimm MO, Horstmann M, Sjödahl G, Höglund M, Steiniche T, Mogensen K, de Reyniès A, Nawroth R, Jordan B, Lin X, Dragicevic D, Ward DG, Goel A, Hurst CD, Raman JD, Warrick JI, Segersten U, Sikic D, van Kessel KEM, Maurer T, Meeks JJ, DeGraff DJ, Bryan RT, Knowles MA, Simic T, Hartmann A, Zwarthoff EC, Malmström PU, Malats N, Real FX, Dyrskjøt L. Lindskrog SV, et al. Nat Commun. 2021 Apr 16;12(1):2301. doi: 10.1038/s41467-021-22465-w. Nat Commun. 2021. PMID: 33863885 Free PMC article.
The molecular landscape in non-muscle-invasive bladder cancer (NMIBC) is characterized by large biological heterogeneity with variable clinical outcomes. ...Spatial proteomics analysis confirms the higher infiltration of class 2b tumors and demonstrates an as …
The molecular landscape in non-muscle-invasive bladder cancer (NMIBC) is characterized by large biological heterogeneity with variabl …
Novel Genetic Subtypes of Urothelial Carcinoma With Differential Outcomes on Immune Checkpoint Blockade.
Sarfaty M, Golkaram M, Funt SA, Al-Ahmadie H, Kaplan S, Song F, Regazzi A, Makarov V, Kuo F, Ostrovnaya I, Seshan V, Zhao C, Greenbaum B, Liu L, Rosenberg JE, Chan TA. Sarfaty M, et al. J Clin Oncol. 2023 Jun 10;41(17):3225-3235. doi: 10.1200/JCO.22.02144. Epub 2023 Mar 16. J Clin Oncol. 2023. PMID: 36927002
PURPOSE: Immune checkpoint blockade (ICB) therapy has significantly improved clinical outcomes in bladder cancer. Identification of correlates of benefit is critical to select appropriate therapy for individual patients. ...CONCLUSION: Together, our study defines mo …
PURPOSE: Immune checkpoint blockade (ICB) therapy has significantly improved clinical outcomes in bladder cancer. Identificati …
Immunotherapy for genitourinary tumors.
Nakayama T, Kitano S. Nakayama T, et al. Int J Urol. 2019 Mar;26(3):326-333. doi: 10.1111/iju.13902. Epub 2019 Feb 1. Int J Urol. 2019. PMID: 30710374 Review.
The present review provides an update about the major achievements and recent advances of immunotherapy in renal cell carcinoma, urothelial carcinoma, and prostate cancer. Although the treatment strategy for renal cell carcinoma and ur …
The present review provides an update about the major achievements and recent advances of immunotherapy in renal cell carcinoma …
Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X, Wang Y, A G, Qu C, Chen J. Zhang X, et al. Front Immunol. 2021 Aug 31;12:721030. doi: 10.3389/fimmu.2021.721030. eCollection 2021. Front Immunol. 2021. PMID: 34531868 Free PMC article.
Further, high PARP1 expression was significantly associated with six immune cells (B cells, CD4+ T cells, CD8+ T cells, macrophages, neutrophils, and dendritic cells) in most tumors, including colon adenocarcinoma (COAD), head and neck squamous cell carcinoma (HNSC) …
Further, high PARP1 expression was significantly associated with six immune cells (B cells, CD4+ T cells, CD8+ T cells, macrophages, neutrop …
A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy.
Jang HJ, Hostetter G, Macfarlane AW, Madaj Z, Ross EA, Hinoue T, Kulchycki JR, Burgos RS, Tafseer M, Alpaugh RK, Schwebel CL, Kokate R, Geynisman DM, Zibelman MR, Ghatalia P, Nichols PW, Chung W, Madzo J, Hahn NM, Quinn DI, Issa JJ, Topper MJ, Baylin SB, Shen H, Campbell KS, Jones PA, Plimack ER. Jang HJ, et al. Clin Cancer Res. 2023 Jun 1;29(11):2052-2065. doi: 10.1158/1078-0432.CCR-22-3642. Clin Cancer Res. 2023. PMID: 36928921 Free PMC article. Clinical Trial.
PURPOSE: On the basis of preclinical evidence of epigenetic contribution to sensitivity and resistance to immune checkpoint inhibitors (ICI), we hypothesized that guadecitabine (hypomethylating agent) and atezolizumab [anti-programmed cell death ligand 1 (PD-L1)] together …
PURPOSE: On the basis of preclinical evidence of epigenetic contribution to sensitivity and resistance to immune checkpoint inhibitors (ICI) …
Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer.
Kerzeli IK, Kostakis A, Türker P, Malmström PU, Hemdan T, Mezheyeuski A, Ward DG, Bryan RT, Segersten U, Lord M, Mangsbo SM. Kerzeli IK, et al. BMC Cancer. 2023 Jun 30;23(1):605. doi: 10.1186/s12885-023-11100-0. BMC Cancer. 2023. PMID: 37391708 Free PMC article.
BACKGROUND: Urothelial bladder cancer is most frequently diagnosed at the non-muscle-invasive stage (NMIBC). ...Single-cell transcriptomics analyses indicated tumour-infiltrating macrophages as a putative source of MMP12. ...
BACKGROUND: Urothelial bladder cancer is most frequently diagnosed at the non-muscle-invasive stage (NMIBC). ...Single-cell …
Clinical and molecular correlates of response to immune checkpoint blockade in urothelial carcinoma with liver metastasis.
Yoshida T, Ohe C, Ito K, Takada H, Saito R, Kita Y, Sano T, Tsuta K, Kinoshita H, Kitamura H, Nishiyama H, Kobayashi T; Japan Urological Oncology Group. Yoshida T, et al. Cancer Immunol Immunother. 2022 Nov;71(11):2815-2828. doi: 10.1007/s00262-022-03204-6. Epub 2022 Apr 20. Cancer Immunol Immunother. 2022. PMID: 35445305 Free PMC article.
Despite recent advancements in immunotherapy, urothelial carcinoma patients with liver metastasis have a poor response to immune checkpoint inhibitors (ICIs) and short survival durations. Here, we investigated the clinical activity and molecular correlates of …
Despite recent advancements in immunotherapy, urothelial carcinoma patients with liver metastasis have a poor response to immu …
Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
Sweis RF, Galsky MD. Sweis RF, et al. Urol Oncol. 2016 Dec;34(12):556-565. doi: 10.1016/j.urolonc.2016.10.006. Epub 2016 Nov 9. Urol Oncol. 2016. PMID: 27836246 Free PMC article. Review.
Urothelial bladder cancer is one of the first cancers recognized to be immunogenic since 40 years ago when the use of bacillus Calmette-Guerin was shown to prevent recurrence. ...Anti-programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1 …
Urothelial bladder cancer is one of the first cancers recognized to be immunogenic since 40 years ago when the use of bacillus …
Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer.
Inman BA, Longo TA, Ramalingam S, Harrison MR. Inman BA, et al. Clin Cancer Res. 2017 Apr 15;23(8):1886-1890. doi: 10.1158/1078-0432.CCR-16-1417. Epub 2016 Nov 30. Clin Cancer Res. 2017. PMID: 27903674 Review.
By blocking the PD-L1/PD-1 immune checkpoint, atezolizumab reduces immunosuppressive signals found within the tumor microenvironment and, consequently, increases T-cell-mediated immunity against the tumor. Atezolizumab has been FDA approved as second-line therapy for advan …
By blocking the PD-L1/PD-1 immune checkpoint, atezolizumab reduces immunosuppressive signals found within the tumor microenvironment and, co …
206 results